Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2022 Filed Jun 13, 2022 23:59 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017325 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:01 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017328 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,519 Underlying: Common Stock · 782 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:01 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Tax withholdingCommon Stock | 280 | $60.74 | $17,007.20 |
DisclosureSEC source: 0001127602-22-017328 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,426 Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:01 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionCommon Stock | 782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017328 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:06 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017330 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,039 Underlying: Common Stock · 317 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:06 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Tax withholdingCommon Stock | 148 | $60.74 | $8,989.52 |
DisclosureSEC source: 0001127602-22-017330 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,750 Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:06 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017330 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:08 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017333 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,793 Underlying: Common Stock · 990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:08 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 462 | $60.74 | $28,061.88 |
DisclosureSEC source: 0001127602-22-017333 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,072 Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:08 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017333 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:13 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017336 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,452 Underlying: Common Stock · 1,026 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:13 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017336 · form4.xml · derivative · entry 4 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,478 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:13 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 1,969 | $60.74 | $119,597.06 |
DisclosureSEC source: 0001127602-22-017336 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,056 Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:13 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 1,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017336 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:13 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017336 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:25 UTC |
Kramer Kelly A.Director
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $31.65 Strike: $61.35 | $501,684.15 |
DisclosureSEC source: 0001127602-22-013713 · form4.xml · derivative · entry 2 Kramer Kelly A. · CIK 0001629885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:25 UTC |
Kramer Kelly A.Director
|
GrantRestricted Stock Unit · Derivative | 2,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013713 · form4.xml · derivative · entry 1 Kramer Kelly A. · CIK 0001629885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,397 Underlying: Common Stock · 2,444 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 5, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:39 UTC |
MANWANI HARISHDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013718 · form4.xml · derivative · entry 3 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:39 UTC |
MANWANI HARISHDirector
|
Tax withholdingCommon Stock | 477 | $61.35 | $29,263.95 |
DisclosureSEC source: 0001127602-22-013718 · form4.xml · nonDerivative · entry 2 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,495 Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:39 UTC |
MANWANI HARISHDirector
|
GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013718 · form4.xml · nonDerivative · entry 1 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,972 F1 · security: Represents 2,444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:29 UTC |
Horning SandraDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $61.35 Strike: $61.35 | $972,458.85 |
DisclosureSEC source: 0001127602-22-013715 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:29 UTC |
Horning SandraDirector
|
GrantRestricted Stock Unit · Derivative | 2,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013715 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,491 Underlying: Common Stock · 2,444 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 5, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:45 UTC |
WELTERS ANTHONYDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013720 · form4.xml · derivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:45 UTC |
WELTERS ANTHONYDirector
|
GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013720 · form4.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,035 F1 · security: Represents 2.444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:48 UTC |
Rodriguez JavierDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013722 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:48 UTC |
Rodriguez JavierDirector
|
GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013722 · form4.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,505 F1 · security: Represents 2,444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:52 UTC |
Lofton Kevin EDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013724 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:52 UTC |
Lofton Kevin EDirector
|
GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013724 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 95,192 F1 · security: Represents 2.444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. F2 · balance_after: Includes 65,874 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. F2 · ownership.nature: Includes 65,874 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:57 UTC |
Bluestone JeffreyDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013726 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:57 UTC |
Bluestone JeffreyDirector
|
GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013726 · form4.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,708 F1 · security: Represents 2,444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:04 UTC |
BARTON JACQUELINE KDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013728 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately on the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:04 UTC |
BARTON JACQUELINE KDirector
|
GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013728 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,343 F1 · security: Represents 2,444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:02 UTC |
Rodriguez JavierDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013117 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:02 UTC |
Rodriguez JavierDirector
|
Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013117 · form4.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:00 UTC |
WELTERS ANTHONYDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013114 · form4.xml · derivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:00 UTC |
WELTERS ANTHONYDirector
|
Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013114 · form4.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:07 UTC |
Lofton Kevin EDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013122 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,830 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F3 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:07 UTC |
Lofton Kevin EDirector
|
Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013122 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 92,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · balance_after: Includes 63,430 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. F2 · ownership.nature: Includes 63,430 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:11 UTC |
MANWANI HARISHDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013124 · form4.xml · derivative · entry 3 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units will vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:11 UTC |
MANWANI HARISHDirector
|
Tax withholdingCommon Stock | 349 | $60.33 | $21,055.17 |
DisclosureSEC source: 0001127602-22-013124 · form4.xml · nonDerivative · entry 2 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,528 Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:11 UTC |
MANWANI HARISHDirector
|
Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013124 · form4.xml · nonDerivative · entry 1 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:15 UTC |
Horning SandraDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013127 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,047 Underlying: Common Stock · 1,112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:15 UTC |
Horning SandraDirector
|
Exercise / conversionCommon Stock | 1,112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013127 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:17 UTC |
Bluestone JeffreyDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013129 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:17 UTC |
Bluestone JeffreyDirector
|
Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013129 · form4.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:21 UTC |
BARTON JACQUELINE KDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013133 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,553 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:21 UTC |
BARTON JACQUELINE KDirector
|
Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013133 · form4.xml · nonDerivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 22:43 UTC |
Lofton Kevin EDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 16,322 | $0.00 Strike: $25.63 | $0.00 |
DisclosureSEC source: 0001127602-22-012762 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,322 shares Expires 2022-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options vested quarterly over the first year of service and were fully vested on May 10, 2013. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 22:43 UTC |
Lofton Kevin EDirector
|
Exercise / conversionCommon Stock | 16,322 | $25.63 | $418,251.25 |
DisclosureSEC source: 0001127602-22-012762 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 90,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 61,207 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. F1 · ownership.nature: Includes 61,207 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 22:31 UTC |
Lofton Kevin EDirector
|
GrantPhantom Stock · Derivative | 36.3498 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-010760 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,007.0776 Underlying: Common Stock · 36.3498 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.